We have placed cookies on your device to improve this website. You can change your cookie settings at any time and receive further information regarding cookies . Otherwise, we will assume you're OK to continue.
You are now leaving www.kedrion.at. Medical information including licensed uses may be different outside of the EU countries.
Kedrion International distributes Kedrion’s plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies in many parts of the world.
Kedrion International was formed in 2012 and continues the pioneering work started by Ked AG in 2005. It organizes Kedrion interests in Europe, the Middle East, and Asia, along with Russia and the Commonwealth of Independent States. Kedrion is a primarily family-owned business that places a high value on the welfare of not only those who benefit from its products but also the people and communities where it operates.
Kedrion around the world
Kedrion Biopharma has a long history of collaboration with the Italian National Health System, and partners the country in its move toward self-sufficiency in plasma-derived products. We bring this experience and the dedication to that goal to potential partners around the world. In recent years Kedrion has expanded its operations – not only into the United States through Kedrion Biopharma Inc., but into Germany and Hungary as well. It now has a market presence in about 100 countries. In addition, it has acquired collection and production capacity as well as the rights to significant products for treating hemophilia and preventing Rh sensitization, a condition which can lead to Hemolytic Disease of the Fetus and the Newborn (HDFN).
Kedrion looks forward to continued expansion and the wider sharing of its experience, know-how and technology to foster self-sufficiency of plasma-derived products in healthcare systems and communities around the world and to bring healthier and less restricted lives to people suffering from rare disorders.
Everyone has the right to life, liberty and security of person*
Sometimes, natural, accidental or social causes obstruct the natural right to life, liberty and personal security. Because of the special nature of its products, Kedrion supports people, communities and institutions in reducing or removing those obstacles that prevent people enjoying such rights. Kedrion helps turn the natural rights (life, liberty, security) into the social right to live in the best possible conditions.
For this reason, it collects and converts, makes active and usable that vital energy that is generated and regenerated, preserved and carried through blood; so that it can be transferred from one human being to the next, and anyone can enjoy one’s fundamental rights.
*Universal Declaration of Human Rights, art. 3.
Kedrion produces and distributes human plasma-derived medicinal products used to treat and prevent rare and debilitating diseases and disorders. Kedrion works to maintain excellent industry standards and aspires to ongoing improvement, in order to retain a leading position in Italy and to increase its share of the international market. It works to strengthen its role as the accredited partner of the medical, scientific and institutional communities.
Kedrion’s ambition is to enhance its worldwide role as a strategic partner of the national health systems of those countries which aim at becoming self-sufficient in the availability of plasma-derived products including technology transfer.
Kedrion produces wealth for investors, employees and for the local community, consistently with its own vision and values: responsibility, transparency, confidence in and respect for people.
To act as responsible global citizens respecting all the communities with whom and for whom we work.
To make accurate and comprehensive information available to all stakeholders.
QUALITY AND SAFETY
To demonstrate care and respect for our clients, our collaborators and our employees by continuous emphasis on the quality and safety of all our products and processes.